Business Wire10.04.18
Stimwave LLC, a medical device manufacturer and independent research institute headquartered in South Florida, announced that Paul LaViolette, managing partner and chief operating officer of SV Health Investors and former chief operating officer of Boston Scientific Corp., and Jeff Goldberg, former president of Al Mann’s medical-technology incubator, have joined Stimwave’s Board of Directors.
“Paul is an inspirational thought leader who has helped grow companies who were disruptive in health care into multi-billion dollar enterprises, while improving the lives of millions,” said Stimwave Chairman and CEO Laura Tyler Perryman. "He will be an outstanding addition to our board."
LaViolette built and ran medical device businesses for 29 years. During his tenure at Boston Scientific, the company grew revenue over 20 times. He integrated two dozen acquisitions and led extensive product development, manufacturing and worldwide commercial organizations.
“It’s an honor and a privilege to come aboard with Stimwave as it deploys its innovative technology to market,” said LaViolette. “Medical devices focused on increased access, minimal invasiveness and state of the art technology are the future of health care, and Stimwave is well positioned to expand the neuromodulation market.”
Goldberg has been an executive and advisor in the health care industry for over 25 years. Recently, he served as chair of the board of Angiotech Pharmaceuticals and Physiotherapy Associates and is now serving as chair of the board of 21st Century Oncology, LifeCare Health Partners, Corizon Health, and M*Modal.
“Jeff Goldberg served a critical role within Al Mann’s enterprises for many years, and Stimwave holds the same principles of creating a technology platform that can benefit patients’ lives, while increasing the market considerably by reimagining how we deliver neuromodulation,” said Perryman. “Familiarity with industry disruptor products such as Stimwave will be invaluable to our future growth plans as we continue to transform our business at an accelerated pace.”
“The opportunity to treat pain without implanting a large battery, like what Laura and the Stimwave team are offering patients and their physicians, represents the same type of dramatic innovation that characterized Al Mann’s most successful companies,” Goldberg said. “I am honored to work with as creative and dynamic a leader with Laura and look forward to our journey together.”
Stimwave’s devices are the premier wireless stimulators, using Wireless Pain Relief technology that allows them to be 95 percent smaller than any other neuromodulation device on the market. These devices treat back and leg pain, as well as treatment for shoulder pain, wrist and elbow pain, knee pain, hip pain and more.
Stimwave LLC is a privately held medical device company engaged in the development, manufacturing, and commercialization of wirelessly powered, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective pain management solution that is easily incorporated into their daily lives. Stimwave’s goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of pain management.
“Paul is an inspirational thought leader who has helped grow companies who were disruptive in health care into multi-billion dollar enterprises, while improving the lives of millions,” said Stimwave Chairman and CEO Laura Tyler Perryman. "He will be an outstanding addition to our board."
LaViolette built and ran medical device businesses for 29 years. During his tenure at Boston Scientific, the company grew revenue over 20 times. He integrated two dozen acquisitions and led extensive product development, manufacturing and worldwide commercial organizations.
“It’s an honor and a privilege to come aboard with Stimwave as it deploys its innovative technology to market,” said LaViolette. “Medical devices focused on increased access, minimal invasiveness and state of the art technology are the future of health care, and Stimwave is well positioned to expand the neuromodulation market.”
Goldberg has been an executive and advisor in the health care industry for over 25 years. Recently, he served as chair of the board of Angiotech Pharmaceuticals and Physiotherapy Associates and is now serving as chair of the board of 21st Century Oncology, LifeCare Health Partners, Corizon Health, and M*Modal.
“Jeff Goldberg served a critical role within Al Mann’s enterprises for many years, and Stimwave holds the same principles of creating a technology platform that can benefit patients’ lives, while increasing the market considerably by reimagining how we deliver neuromodulation,” said Perryman. “Familiarity with industry disruptor products such as Stimwave will be invaluable to our future growth plans as we continue to transform our business at an accelerated pace.”
“The opportunity to treat pain without implanting a large battery, like what Laura and the Stimwave team are offering patients and their physicians, represents the same type of dramatic innovation that characterized Al Mann’s most successful companies,” Goldberg said. “I am honored to work with as creative and dynamic a leader with Laura and look forward to our journey together.”
Stimwave’s devices are the premier wireless stimulators, using Wireless Pain Relief technology that allows them to be 95 percent smaller than any other neuromodulation device on the market. These devices treat back and leg pain, as well as treatment for shoulder pain, wrist and elbow pain, knee pain, hip pain and more.
Stimwave LLC is a privately held medical device company engaged in the development, manufacturing, and commercialization of wirelessly powered, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective pain management solution that is easily incorporated into their daily lives. Stimwave’s goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of pain management.
